

David Pittrow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7724905/publications.pdf>

Version: 2024-02-01

53
papers

2,896
citations

257357

24
h-index

175177

52
g-index

57
all docs

57
docs citations

57
times ranked

3003
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. <i>European Respiratory Journal</i> , 2017, 50, 1700740.	3.1	489
2	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. <i>International Journal of Cardiology</i> , 2013, 168, 871-880.	0.8	357
3	Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2016, 68, 368-378.	1.2	244
4	Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. <i>European Respiratory Journal</i> , 2015, 46, 186-196.	3.1	194
5	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. <i>Respiratory Research</i> , 2017, 18, 139.	1.4	135
6	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 60, 2102311.	3.1	124
7	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1435-1444.	0.3	104
8	Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. <i>European Respiratory Journal</i> , 2020, 56, 1902279.	3.1	102
9	Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. <i>PLoS ONE</i> , 2015, 10, e0141911.	1.1	80
10	Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. <i>Clinical Research in Cardiology</i> , 2018, 107, 548-553.	1.5	77
11	Risk assessment in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 51, 1702606.	3.1	67
12	Usefulness of Direct Oral Anticoagulants in Adult Congenital Heart Disease. <i>American Journal of Cardiology</i> , 2016, 117, 450-455.	0.7	64
13	Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. <i>European Respiratory Journal</i> , 2018, 52, 1800248.	3.1	61
14	Incidence and prevalence of pulmonary arterial hypertension in Germany. <i>International Journal of Cardiology</i> , 2016, 203, 612-613.	0.8	60
15	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2022, 59, 2102024.	3.1	57
16	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 937-948.	5.2	57
17	Pulmonary Hypertension in Patients With COPD. <i>Chest</i> , 2021, 160, 678-689.	0.4	55
18	Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2021, 58, 2101483.	3.1	48

#	ARTICLE	IF	CITATIONS
19	Risk stratification in pulmonary arterial hypertension using Bayesian analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000008.	3.1	38
20	Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study. <i>European Journal of Haematology</i> , 2017, 99, 169-177.	1.1	29
21	The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. <i>Clinical Research in Cardiology</i> , 2018, 107, 460-470.	1.5	29
22	Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT). <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 62, 241-249.	0.8	29
23	Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 716-721.	0.3	28
24	Pattern of prescriptions issued by nursing home-based physicians versus office-based physicians for frail elderly patients in German nursing homes. <i>Pharmacoepidemiology and Drug Safety</i> , 2003, 12, 595-599.	0.9	26
25	Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study. <i>Atherosclerosis</i> , 2017, 266, 24-30.	0.4	26
26	Improving medical care and prevention in adults with congenital heart disease—reflections on a global problem—part I: development of congenital cardiology, epidemiology, clinical aspects, heart failure, cardiac arrhythmia. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 705-715.	0.7	26
27	Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 601279.	1.2	24
28	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.	1.3	23
29	Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry: Table A1. <i>BMJ Open Respiratory Research</i> , 2014, 1, e000010.	1.2	22
30	Improved risk stratification in prevention by use of a panel of selected circulating microRNAs. <i>Scientific Reports</i> , 2017, 7, 4511.	1.6	22
31	Longitudinal change instead of baseline testosterone predicts depressive symptoms. <i>Psychoneuroendocrinology</i> , 2018, 89, 7-12.	1.3	22
32	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1456.	1.0	21
33	Improved Detection of Paroxysmal Atrial Fibrillation Utilizing a Software-Assisted Electrocardiogram Approach. <i>PLoS ONE</i> , 2014, 9, e89328.	1.1	21
34	Cardiovascular risk algorithms in primary care: Results from the DETECT study. <i>Scientific Reports</i> , 2019, 9, 1101.	1.6	15
35	Resource use and costs in systolic heart failure according to disease severity: a pooled analysis from the German Competence Network Heart Failure. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2012, 20, 23-30.	0.8	14
36	Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 165-179.	1.5	14

#	ARTICLE	IF	CITATIONS
37	Improving medical care and prevention in adults with congenital heart disease—reflections on a global problem—part II: infective endocarditis, pulmonary hypertension, pulmonary arterial hypertension and aortopathy. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 716-724.	0.7	14
38	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 177, 106241.	1.3	13
39	Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1125-1133.	0.8	10
40	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 971-981.	0.3	9
41	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1255-1268.	0.7	8
42	Rationale, design, and methodology of the observational INSIGHTS-SVT study on the current state of care and outcomes of patients with superficial vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 553-560.e1.	0.9	6
43	Response to Letters Regarding Article, “Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)”. <i>Circulation</i> , 2014, 130, e110-2.	1.6	5
44	Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients. <i>Immunotherapy</i> , 2020, 12, 131-139.	1.0	5
45	Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2012, 20, 289-296.	0.8	3
46	Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases. <i>Immunotherapy</i> , 2022, 14, 135-143.	1.0	3
47	1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: Prospective 3A registry. <i>International Journal of Cardiology</i> , 2014, 176, 589-594.	0.8	2
48	Two-Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non-Interventional Prospective Study. <i>Journal of Clinical Hypertension</i> , 2016, 18, 647-654.	1.0	2
49	Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1045-1053.	1.0	2
50	Impact of a Low-Dose Combination of Isradipine SRO and Spirapril on Left Ventricular Mass and Left Ventricular Performance in Patients with Hypertension and Left Ventricular Hypertrophy. <i>Clinical Drug Investigation</i> , 2002, 22, 667-675.	1.1	1
51	Testosterone is not associated with traits of optimism or pessimism: Observational evidence from the prospective DETECT study. <i>PLoS ONE</i> , 2018, 13, e0207870.	1.1	1
52	Outcomes of medical management of peripheral arterial disease in general practice: follow-up results of the PACE-PAD Study. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2010, 18, 523-532.	0.8	0
53	Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2021, 57, 2100283.	3.1	0